Brief: Can-Fite To Treat Decompensated Liver Cirrhosis Patients With Namodenoson Under Compassionate Use Setting
13/03/2023 11:29
March 13 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN-FITE TO TREAT DECOMPENSATED LIVER CIRRHOSIS PATIENTS
WITH
NAMODENOSON UNDER COMPASSIONATE USE SETTING
Source text for Eikon: ID:nBw269jnVa
Further company coverage: CANF.TA
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage